A team of WilmerHale lawyers advised Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) in connection with its proposed $8.8 billion acquisition by Takeda Pharmaceutical Company Limited (TSE: 4502) through a cash tender offer. The deal is the largest overseas acquisition by a Japanese drug manufacturer.
Serving as Millennium’s M&A counsel in the transaction are WilmerHale lawyers David Redlick
, Hal Leibowitz
, Jeffrey Hermanson
, Brian Johnson
, Emily Babalas, Jason Kropp
and Sonia Bednarowski. The M&A team is assisted by antitrust partners William Kolasky
and Sven Voeckler
, and tax partners William Schmidt
and Robert Burke
WilmerHale has served as primary outside counsel to Millennium since the early 1990s. Millennium is a leading biopharmaceutical company based in Cambridge, Massachusetts that markets VELCADE, a novel cancer product, and has oncology and inflammation product candidates in various stages of development.
for Millennium Pharmaceutical’s complete press release.